[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100444615":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":26,"centralContacts":30,"locations":40,"responsibleParty":59,"collaborators":26,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":69,"eligibilityCriteria":70,"healthyVolunteers":71,"sex":72,"minAge":73,"maxAge":74,"enrollmentInfo":75,"targetDuration":26,"studyType":78,"phases":79,"briefSummary":81,"conditions":82,"keywords":84,"overallStatus":43,"whyStopped":26,"lastUpdateSubmitDate":89,"lastUpdatePostDateStruct":90,"startDateStruct":93,"completionDateStruct":95,"leadSponsor":97,"locationsCount":98},{"fullName":5,"class":6},"Penn State University","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Salsalate","EXPERIMENTAL","3000 mg\u002Fday salsalate (1500 mg twice daily) for 5 days",[13],"Drug: Salsalate Pill",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","1 capsule contain microcrystalline cellulose filler (twice daily) for 5 days",[19],"Drug: Placebo",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Salsalate Pill","Salsalate acts as an NFkB inhibitor to reduce systemic inflammation",[9],null,{"type":22,"name":15,"description":28,"armGroupLabels":29,"otherNames":26},"Placebo for the salsalate intervention",[15],[31,36],{"name":32,"role":33,"phone":34,"phoneExt":26,"email":35},"Lacy M Alexander, Ph.D.","CONTACT","8148671781","lma191@psu.edu",{"name":37,"role":33,"phone":38,"phoneExt":26,"email":39},"Susan Slimak, RN","814-863-8554","sks31@psu.edu",[41],{"facility":42,"status":43,"city":44,"state":45,"zip":46,"country":47,"countryCode":48,"cosmosGeoPoint":49,"geoPoint":54,"contacts":55},"The Pennsylvania State University","RECRUITING","University Park","Pennsylvania","16801","United States","US",{"type":50,"coordinates":51},"Point",[52,53],-77.85639,40.80201,{"lat":53,"lon":52},[56],{"name":57,"role":33,"phone":58,"phoneExt":26,"email":35},"Lacy M Alexander, PhD","814-867-1781",{"type":60,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"PRINCIPAL_INVESTIGATOR","Lacy Alexander","Professor of Kinesiology","100444615","early-phase-1-endometriosis-and-microvascular-dysfunction-role-of-inflammation-100444615",false,"NCT05069740","Endometriosis and Microvascular Dysfunction: Role of Inflammation","Mechanisms and Interventions Addressing Accelerated Cardiovascular Disease Risk in Endometriosis","Endo3\u002FSA2","Inclusion Criteria:\n\n* Healthy women between the ages of 18 and 45 years (Controls), taking oral contraceptive or with regular menses every 26-34 days\n* Women between the ages of 18 and 45 years with endometriosis (diagnosis by prior laparoscopy by subject's own physician \\\u003C5 years prior, and reported by the subject to the researchers)\n* Tylenol if the subject has acute pain is allowed\n* Contraceptive use is allowed\n\nExclusion Criteria:\n\n* Use of nicotine-containing products (e.g. smoking, chewing tobacco, etc.)\n* Diabetes (HbA1C 6.5%)\n* BP\\>140\u002F90\n* Taking pharmacotherapy that could alter peripheral vascular control (e.g. insulin sensitizing, cardiovascular medications)\n* Pregnancy\n* Breastfeeding\n* Taking illicit and\u002For recreational drugs\n* Abnormal liver function\n* Rash, skin disease, disorders of pigmentation, known skin allergies\n* Diagnosed or suspected metabolic or cardiovascular disease\n* Persistent unexplained elevations of serum transaminases\n* Known allergy to latex or investigative substances (including salsalate or simvastatin)\n* History of gastrointestinal bleeding",true,"FEMALE","18 Years","45 Years",{"count":76,"type":77},24,"ESTIMATED","INTERVENTIONAL",[80],"EARLY_PHASE1","The purpose of this study is to better understand the underlying mechanisms associated with elevated cardiovascular disease risk in women with endometriosis, and to measure the effectiveness of emerging endometriosis treatments on outcomes specific to cardiovascular dysfunction.\n\nEpidemiologic data demonstrate a clear association between endometriosis, reproductive risk factors, inflammation and cardiovascular (CV) risk. Circulating factors, low-density lipoprotein (LDL) and oxidized LDL (oxLDL), are two of many biomarkers of cardiovascular and inflammatory disease of endometriosis. An important signaling mechanism through which circulating LDL and oxLDL act is the lectin-like oxidized LDL receptor (LOX-1). LOX-1 signal transduction functionally results in pronounced endothelial dysfunction, a hallmark of CV. The investigators hypothesis that one factor mediating the elevated risk of cardiovascular disease in endometriosis is systemic inflammation and activation of LOX-1 receptor mechanisms.",[83],"Endometriosis",[85,86,87,88],"skin blood flow","inflammation","Lectin-like oxidized LDL receptor (LOX-1)","intradermal microdialysis","2026-07-24",{"date":91,"type":92},"2026-07-27","ACTUAL",{"date":94,"type":92},"2022-01-01",{"date":96,"type":77},"2026-12-31",{"name":5,"class":6},1]